Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is initiating a Phase 1 clinical study titled A PHASE 1, ...

ROCKVILLE, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Today the American Kidney Fund (AKF) announces the second annual APOL1-Mediated Kidney Disease (AMKD) Awareness Day, a day to educate communities ...

ROCKVILLE, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Today the American Kidney Fund (AKF) announces the second annual APOL1-Mediated Kidney Disease (AMKD) Awareness Day, a day to educate communities ...

"The link between APOL1 gene variants and kidney disease was discovered just 15 years ago, and as we learn more about this serious disease, we are working proactively to spark conversations in at-risk ...

Those who have variants in both copies of the APOL1 gene have a 1 in 5 chance of developing kidney disease. "A lot of people don't even know about how prevalent the APOL1 gene is in the African ...

Everyone has two copies of the apolipoprotein L1 (APOL1) gene – one from each parent – but Black Americans of West and Central African ancestry are more likely to have changes (variants or mutations) ...

Maze Therapeutics, a kidney disease therapy developer, recently IPO-ed with a market cap of $487mn and significant early-stage investor backing. Lead asset MZE829 targets APOL1 Kidney Disease ...